Marco Meglio

An excellent epilepsy outcome was achieved in 66% of cases over a median follow-up of 41 months and was not significantly associated with the type of surgery undergone.

The treatment device from Theranica also demonstrated a positive impact on patients who experienced menstrual cramps or pelvic pain.

Eli Lilly plans on submitting a biologics license application for donanemab under the accelerated approval pathway based on data from the phase 2 TRAILBLAZER-ALZ study.

Calli L. Cook, NP, DNP, nurse practitioner, Woodruff School of Nursing, Emory University, detailed her vision for creating change within the neurology field by incorporating advanced practice clinicians.

The decision to grant breakthrough therapy designation was based off the proof-of-concept phase 2b study which explored the impact of lecanemab, formerly BAN2401, on reducing brain amyloid beta and clinical decline.

A significantly higher percentage of patients treated with ublituximab compared to those on teriflunomide achieved no evidence of disease activity status.

Michael J. Thorpy, MD, director of the Sleep-Wake Disorders Center at Montefiore Medical Center, discussed how telemedicine has factored in the care for patients with sleep disorders throughout the pandemic.

At 2 hours after the start of the infusion, headache pain freedom was reported by 23.5% of patients receiving eptinezumab compared to 12% in the placebo group.

The duo from Cleveland Clinic addressed several of their research projects presented at AHS 2021 that covered a range of COVID-19 related topics, including the unknowns about associated headaches.

The exploratory end point of the ability to thrive in symptomatic patients was met by 30% of those in a subanalysis of STR1VE-EU, compared to none in the comparative Preclinical Neuromuscular Clinical Research study.

At baseline, a negative correlation was noted between average cognition and VAN importance in both groups, indicating that lower VAN importance is related to a higher average cognition.

About half of national (49%) and international trainees rarely or never counseled patients on sudden death in epilepsy, despite the majority reporting seeing at least 45 patients with the condition during their training.

After showing early success, zavegepant eyes a pivotal phase 2/3 trial with potential regulatory submission around the corner.

The median time from randomization to atrial fibrillation detection was 99 days in the cardiac monitor group compared to 181 days for the control group.

Primary and secondary end points of the trial will assess safety and both cognitive and functional efficacy, measured through ADAS-Cog, ADCS-ADL, and CDR-SB.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center detailed the overall state of sleep care and the advantages the investigational FT218 brings to the growing pipeline.

A pharmacokinetic/pharmacodynamic model indicated that the exposures predicted with a higher dose of nusinersen may lead to more clinically meaningful increases of at least 5 points on CHOP INTEND score.

Higher maximum third-trimester ASM blood levels were associated with significantly lower BSID-III scores for the motor domain and lower scores for the general adaptive domain.

When paired with the Percept PC device, SenSight expands on BrainSense technology, enabling clinicians to capture and record enhanced, directional local field potential information from the implanted lead.

The FDA-approved agent demonstrated meaningful reduction in the frequency of cataplexy attacks in adults with narcolepsy, including patients with a high symptom burden.

The HINE-2 motor milestone total score in those treated with nusinersen increased steadily from a baseline mean of 1.46 to 11.86 at day 1135, representing a clinically significant change of 10.43 points.

The findings support previous data that showed no differences between telemedicine and traditional consultations in HIT-6 assessment scores over a long-term period.

For patients treated with pimavanserin in investigational doses of 8.5 mg or 17 mg in the previous studies, further improvement was observed during the open-label extension with 34-mg pimavanserin.

Researchers used a connected network of studies that were generally well balanced in terms of key baseline characteristics, such as baseline MMD and use of prior therapies, to compare preventive treatments.

The director for the Headache Center of Southern California discussed his research presented at AHS 2021 which evaluated a combination of onabotunlinumtoxinA and CGRPs in patients with chronic migraine.

Absence of photophobia, phonophobia, and nausea were achieved in a similar percentage of perimenstrual and non-perimenstrual ubrogepant-treated attacks.

These real-world findings confirm that a 156- to 195-unit dose of onabotulinumtoxinA is efficacious and safe, consistent with findings from the PREEMPT clinical trials.

Treatment with eptinezumab resulted in reduced burdensome features of headache episodes including severe pain, photophobia, phonophobia, nausea, and limited physical activity.

Treatment with INP104 was associated with high rates of symptoms freedom and may be a promising new acute treatment for patients with migraine.

More than 80% of participants experienced at least 50% reduction in monthly migraine days, while more than 60% and just under 50% experienced at least 75% and 100% reductions.